Literature DB >> 22009463

Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Rebecca M Minter1, Diane M Simeone.   

Abstract

BACKGROUND: This article reviews the current literature and recommendations pertaining to the management of nonfunctioning pancreatic neuroendocrine tumors. DISCUSSION: In recent years the detection of nonfunctioning pancreatic neuroendocrine tumors has increased coincident with the increased use of cross-sectional imaging and is now thought to represent 2-10% of all pancreatic tumors. Improved understanding of the biology and behavior of these heterogeneous tumors is needed to guide therapy. The present review discusses diagnostics, therapeutics including emerging molecular analytics, and surveillance recommendations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009463     DOI： 10.1007/s11605-011-1693-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


  74 in total

Review 1.  Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors.

Authors:  Florencia G Que; Juan M Sarmiento; David M Nagorney
Journal:  Cancer Control       Date:  2002 Jan-Feb       Impact factor: 3.302

2.  Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Authors:  Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker
Journal:  Transplantation       Date:  2002-02-15       Impact factor: 4.939

3.  Long-term follow-up of patients with multiple endocrine neoplasia type 1.

Authors:  Akihiro Sakurai; Miyuki Katai; Koh Yamashita; Jun-Ichiro Mori; Yoshimitsu Fukushima; Kiyoshi Hashizume
Journal:  Endocr J       Date:  2007-03-20       Impact factor: 2.349

4.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

7.  Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.

Authors:  Peter Langer; Peter H Kann; Volker Fendrich; Gerd Richter; Saskia Diehl; Matthias Rothmund; Detlef K Bartsch
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

8.  Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations.

Authors:  S K Libutti; P L Choyke; D L Bartlett; H Vargas; M Walther; I Lubensky; G Glenn; W M Linehan; H R Alexander
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

9.  Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors.

Authors:  Tetsuhide Ito; Masao Tanaka; Hironobu Sasano; Yoshiyuki R Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Masayuki Imamura; Ken Kawabe; Kazuhiko Nakamura
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 6.772

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064
View more
  4 in total

Review 1.  AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.

Authors:  Miguel F Herrera; Göran Åkerström; Peter Angelos; Clive S Grant; Ana O Hoff; Juan Pablo Pantoja; Rocio Pérez-Johnston; Dushyant V Sahani; Richard J Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

2.  Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.

Authors:  Iris H Wei; Charles M Harmon; Massimo Arcerito; Debbie F Cheng; Rebecca M Minter; Diane M Simeone
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

Review 3.  Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies.

Authors:  Ersin Gürkan Dumlu; Derya Karakoç; Arif Özdemir
Journal:  Int Surg       Date:  2015-01-15

4.  Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection.

Authors:  Dezhi Li; Yu Zhou; Yanhui Liu; Ye Lin; Min Yu; Xin Lu; Bowen Huang; Zhonghai Sun; Zhixiang Jian; Baohua Hou
Journal:  Onco Targets Ther       Date:  2018-03-06       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.